| Primary | Period 1: Percent Absolute Bioavailability (%F) for TAK-831 | Bioavailability is defined as the proportion of a drug which enters the circulation when introduced into the body and so is able to have an active effect. Percent absolute bioavailability, calculated for plasma TAK-831 as [Actual Dose (IV) x AUCinf (oral)] / [Actual Dose (oral) x AUCinf (IV)] x 100. | PK-evaluable population included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile. Participants who received the oral dose of TAK-831 5 X 100 mg tablets and 50 ug IV dose in Treatment Period 1 were evaluated for this outcome measure. | Posted | | Geometric Mean | Geometric Coefficient of Variation | percent absolute bioavailability | | Day 1 pre-dose and at multiple time points (up to 96.5 hours) post-dose in Treatment Period 1 | | | | ID | Title | Description |
|---|
| OG000 | TAK-831 500 mg + [14C]TAK-831 50 μg | TAK-831 5 X 100 mg tablets, orally, followed by [14C]TAK-831 50 μg (approximately 1 μCi), 15-minute IV infusion, once on Day 1 of Treatment Period 1. |
| | | Title | Denominators | Categories |
|---|
| | |
| |
| Primary | Period 2: Total Radioactivity Expressed as Cumulative Percentage of Dose of [14C]TAK-831 Eliminated in Urine and Feces Combined [Combined Cum%Dose] | | PK-evaluable population included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile. Participants who received the oral dose of [14C]TAK-831 500 mg oral suspension in Treatment Period 2 were evaluated for this outcome measure. | Posted | | Geometric Mean | Geometric Coefficient of Variation | percentage of dose | | Day 1 pre-dose and at multiple time points (up to 240 hours) post-dose in Treatment Period 2 | | | | ID | Title | Description |
|---|
| OG000 | [14C]TAK-831 500 mg | [14C]TAK-831 500 mg (approximately 100 μCi), suspension, orally, under fasted state, once on Day 1 of Treatment Period 2. |
| |
| Primary | Period 2: Total Radioactivity Expressed as Cumulative Amount of [14C]TAK-831 Eliminated in Urine and Feces Combined (Combined CumAe) | | PK-evaluable population included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile. Participants who received the oral dose of [14C]TAK-831 500 mg oral suspension in Treatment Period 2 were evaluated for this outcome measure. | Posted | | Geometric Mean | Geometric Coefficient of Variation | mg equivalents (eq) of parent drug | | Day 1 pre-dose and at multiple time points (up to 240 hours) post-dose in Treatment Period 2 | | | | ID | Title | Description |
|---|
| OG000 | [14C]TAK-831 500 mg | [14C]TAK-831 500 mg (approximately 100 μCi), suspension, orally, under fasted state, once on Day 1 of Treatment Period 2. |
| |
| Primary | Period 2: Percentage of Administered Radioactive Dose of [14C]TAK-831 Excreted in Urine (Cum%Dose [UR]) | | PK-evaluable population included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile. Participants who received the oral dose of [14C]TAK-831 500 mg oral suspension in Treatment Period 2 were evaluated for this outcome measure. | Posted | | Geometric Mean | Geometric Coefficient of Variation | percentage of dose | | Day 1 pre-dose and at multiple time points (up to 240 hours) post-dose in Treatment Period 2 | | | | ID | Title | Description |
|---|
| OG000 | [14C]TAK-831 500 mg | [14C]TAK-831 500 mg (approximately 100 μCi), suspension, orally, under fasted state, once on Day 1 of Treatment Period 2. |
| |
| Primary | Period 2: Percentage of Administered Radioactive Dose of [14C]TAK-831 Excreted in Feces (Cum%Dose [Fe]) | | PK-evaluable population included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile. Participants who received the oral dose of [14C]TAK-831 500 mg oral suspension in Treatment Period 2 were evaluated for this outcome measure. | Posted | | Geometric Mean | Geometric Coefficient of Variation | percentage of dose | | Day 1 pre-dose and at multiple time points (up to 240 hours) post-dose in Treatment Period 2 | | | | ID | Title | Description |
|---|
| OG000 | [14C]TAK-831 500 mg | [14C]TAK-831 500 mg (approximately 100 μCi), suspension, orally, under fasted state, once on Day 1 of Treatment Period 2. |
| |
| Primary | Period 2: Cmax: Maximum Observed Plasma Concentration of TAK-831 | | PK-evaluable population included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile. Participants who received the oral dose of [14C]TAK-831 500 mg oral suspension in Treatment Period 2 were evaluated for this outcome measure. | Posted | | Geometric Mean | Geometric Coefficient of Variation | ng/mL | | Day 1 pre-dose and at multiple time points (up to 240 hours) post-dose | | | | ID | Title | Description |
|---|
| OG000 | [14C]TAK-831 500 mg | [14C]TAK-831 500 mg (approximately 100 μCi), suspension, orally, under fasted state, once on Day 1 of Treatment Period 2. |
| |
| Primary | Period 2: Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) of TAK-831 | | PK-evaluable population included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile. Participants who received the oral dose of [14C]TAK-831 500 mg oral suspension in Treatment Period 2 were evaluated for this outcome measure. | Posted | | Median | Full Range | hours (hr) | | Day 1 pre-dose and at multiple time points (up to 240 hours) post-dose in Treatment Period 2 | | | | ID | Title | Description |
|---|
| OG000 | [14C]TAK-831 500 mg | [14C]TAK-831 500 mg (approximately 100 μCi), suspension, orally, under fasted state, once on Day 1 of Treatment Period 2. |
| |
| Primary | Period 2: t(1/2)z: Terminal Disposition Phase Half-life of TAK-831 in Plasma | | PK-evaluable population included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile. Participants who received the oral dose of [14C]TAK-831 500 mg oral suspension in Treatment Period 2 were evaluated for this outcome measure. | Posted | | Mean | Standard Deviation | hr | | Day 1 pre-dose and at multiple time points (up to 240 hours) post-dose in Treatment Period 2 | | | | ID | Title | Description |
|---|
| OG000 | [14C]TAK-831 500 mg | [14C]TAK-831 500 mg (approximately 100 μCi), suspension, orally, under fasted state, once on Day 1 of Treatment Period 2. |
| |
| Primary | Period 2: AUCinf: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity of TAK-831 | | PK-evaluable population included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile. Participants who received the oral dose of [14C]TAK-831 500 mg oral suspension in Treatment Period 2 were evaluated for this outcome measure. | Posted | | Geometric Mean | Geometric Coefficient of Variation | ng*hr/mL | | Day 1 pre-dose and at multiple time points (up to 240 hours) post-dose in Treatment Period 2 | | | | ID | Title | Description |
|---|
| OG000 | [14C]TAK-831 500 mg | [14C]TAK-831 500 mg (approximately 100 μCi), suspension, orally, under fasted state, once on Day 1 of Treatment Period 2. |
| |
| Primary | Period 2: AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration of TAK-831 | | PK-evaluable population included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile. Participants who received the oral dose of [14C]TAK-831 500 mg oral suspension in Treatment Period 2 were evaluated for this outcome measure. | Posted | | Geometric Mean | Geometric Coefficient of Variation | ng*hr/mL | | Day 1 pre-dose and at multiple time points (up to 240 hours) post-dose in Treatment Period 2 | | | | ID | Title | Description |
|---|
| OG000 | [14C]TAK-831 500 mg | [14C]TAK-831 500 mg (approximately 100 μCi), suspension, orally, under fasted state, once on Day 1 of Treatment Period 2. |
| |
| Primary | Period 2: Cmax: Maximum Observed Plasma Radioactivity Concentration | | PK-evaluable population included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile. Participants who received the oral dose of [14C]TAK-831 500 mg oral suspension in Treatment Period 2 were evaluated for this outcome measure. | Posted | | Geometric Mean | Geometric Coefficient of Variation | ng eq/mL | | Day 1 pre-dose and at multiple time points (up to 240 hours) post-dose in Treatment Period 2 | | | | ID | Title | Description |
|---|
| OG000 | [14C]TAK-831 500 mg | [14C]TAK-831 500 mg (approximately 100 μCi), suspension, orally, under fasted state, once on Day 1 of Treatment Period 2. |
| |
| Primary | Period 2: Tmax: Time to Reach the Maximum Plasma Radioactivity Concentration (Cmax) | | PK-evaluable population included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile. Participants who received the oral dose of [14C]TAK-831 500 mg oral suspension in Treatment Period 2 were evaluated for this outcome measure. | Posted | | Median | Full Range | hr | | Day 1 pre-dose and at multiple time points (up to 240 hours) post-dose in Treatment Period 2 | | | | ID | Title | Description |
|---|
| OG000 | [14C]TAK-831 500 mg | [14C]TAK-831 500 mg (approximately 100 μCi), suspension, orally, under fasted state, once on Day 1 of Treatment Period 2. |
| |
| Primary | Period 2: t(1/2)z: Terminal Disposition Phase Half-life of Plasma Radioactivity Concentration | | PK-evaluable population included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile. Participants who received the oral dose of [14C]TAK-831 500 mg oral suspension in Treatment Period 2 were evaluated for this outcome measure. | Posted | | Mean | Standard Deviation | hr | | Day 1 pre-dose and at multiple time points (up to 240 hours) post-dose in Treatment Period 2 | | | | ID | Title | Description |
|---|
| OG000 | [14C]TAK-831 500 mg | [14C]TAK-831 500 mg (approximately 100 μCi), suspension, orally, under fasted state, once on Day 1 of Treatment Period 2. |
| |
| Primary | Period 2: AUCinf: Area Under the Plasma Radioactivity Concentration-time Curve From Time 0 to Infinity | | PK-evaluable population included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile. Participants who received the oral dose of [14C]TAK-831 500 mg oral suspension in Treatment Period 2 were evaluated for this outcome measure. | Posted | | Geometric Mean | Geometric Coefficient of Variation | ng eq*hr/mL | | Day 1 pre-dose and at multiple time points (up to 240 hours) post-dose in Treatment Period 2 | | | | ID | Title | Description |
|---|
| OG000 | [14C]TAK-831 500 mg | [14C]TAK-831 500 mg (approximately 100 μCi), suspension, orally, under fasted state, once on Day 1 of Treatment Period 2. |
| |
| Primary | Period 2: AUClast: Area Under the Plasma Radioactivity Concentration-time Curve From Time 0 to Last Quantifiable Concentration | | PK-evaluable population included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile. Participants who received the oral dose of [14C]TAK-831 500 mg oral suspension in Treatment Period 2 were evaluated for this outcome measure. | Posted | | Geometric Mean | Geometric Coefficient of Variation | ng eq*hr/mL | | Day 1 pre-dose and at multiple time points (up to 240 hours) post-dose in Treatment Period 2 | | | | ID | Title | Description |
|---|
| OG000 | [14C]TAK-831 500 mg | [14C]TAK-831 500 mg (approximately 100 μCi), suspension, orally, under fasted state, once on Day 1 of Treatment Period 2. |
| |
| Primary | Period 2: Cmax: Maximum Observed Whole Blood Radioactivity Concentration | | PK-evaluable population included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile. Participants who received the oral dose of [14C]TAK-831 500 mg oral suspension in Treatment Period 2 were evaluated for this outcome measure. | Posted | | Geometric Mean | Geometric Coefficient of Variation | ng eq/g | | Day 1 pre-dose and at multiple time points (up to 240 hours) post-dose in Treatment Period 2 | | | | ID | Title | Description |
|---|
| OG000 | [14C]TAK-831 500 mg | [14C]TAK-831 500 mg (approximately 100 μCi), suspension, orally, under fasted state, once on Day 1 of Treatment Period 2. |
| |
| Primary | Period 2: Tmax: Time to Reach the Maximum Whole Blood Radioactivity Concentration (Cmax) | | PK-evaluable population included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile. Participants who received the oral dose of [14C]TAK-831 500 mg oral suspension in Treatment Period 2 were evaluated for this outcome measure. | Posted | | Median | Full Range | hr | | Day 1 pre-dose and at multiple time points (up to 240 hours) post-dose in Treatment Period 2 | | | | ID | Title | Description |
|---|
| OG000 | [14C]TAK-831 500 mg | [14C]TAK-831 500 mg (approximately 100 μCi), suspension, orally, under fasted state, once on Day 1 of Treatment Period 2. |
| |
| Primary | Period 2: t(1/2)z: Terminal Disposition Phase Half-life of Whole Blood Radioactivity Concentration | | PK-evaluable population included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile. Participants who received the oral dose of [14C]TAK-831 500 mg oral suspension in Treatment Period 2 were evaluated for this outcome measure. | Posted | | Mean | Standard Deviation | hr | | Day 1 pre-dose and at multiple time points (up to 240 hours) post-dose in Treatment Period 2 | | | | ID | Title | Description |
|---|
| OG000 | [14C]TAK-831 500 mg | [14C]TAK-831 500 mg (approximately 100 μCi), suspension, orally, under fasted state, once on Day 1 of Treatment Period 2. |
| |
| Primary | Period 2: AUCinf: Area Under the Whole Blood Radioactivity Concentration-time Curve From Time 0 to Infinity | | PK-evaluable population included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile. Participants who received the oral dose of [14C]TAK-831 500 mg oral suspension in Treatment Period 2 were evaluated for this outcome measure. | Posted | | Geometric Mean | Geometric Coefficient of Variation | ng eq*hr/g | | Day 1 pre-dose and at multiple time points (up to 240 hours) post-dose in Treatment Period 2 | | | | ID | Title | Description |
|---|
| OG000 | [14C]TAK-831 500 mg | [14C]TAK-831 500 mg (approximately 100 μCi), suspension, orally, under fasted state, once on Day 1 of Treatment Period 2. |
| |
| Primary | Period 2: AUClast: Area Under the Whole Blood Radioactivity Concentration-time Curve From Time 0 to Last Quantifiable Concentration | | PK-evaluable population included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile. Participants who received the oral dose of [14C]TAK-831 500 mg oral suspension in Treatment Period 2 were evaluated for this outcome measure. | Posted | | Geometric Mean | Geometric Coefficient of Variation | ng eq*hr/g | | Day 1 pre-dose and at multiple time points (up to 240 hours) post-dose in Treatment Period 2 | | | | ID | Title | Description |
|---|
| OG000 | [14C]TAK-831 500 mg | [14C]TAK-831 500 mg (approximately 100 μCi), suspension, orally, under fasted state, once on Day 1 of Treatment Period 2. |
| |
| Primary | Period 2: CLR: Renal Clearance for TAK-831 in Urine | | PK-evaluable population included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile. Participants who received the oral dose of [14C]TAK-831 500 mg oral suspension in Treatment Period 2 were evaluated for this outcome measure. | Posted | | Geometric Mean | Geometric Coefficient of Variation | L/hr | | Day 1 pre-dose and at multiple time points (up to 240 hours) post-dose | | | | ID | Title | Description |
|---|
| OG000 | [14C]TAK-831 500 mg | [14C]TAK-831 500 mg (approximately 100 μCi), suspension, orally, under fasted state, once on Day 1 of Treatment Period 2. |
| |
| Secondary | Period 1: Ceoi: Plasma Concentration at the End of Infusion for [14C]TAK-831 | | PK-evaluable population included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile. Participants who received the [14C]TAK-831 50 μg IV infusion in Period 1 were evaluated for this outcome measure. | Posted | | Geometric Mean | Geometric Coefficient of Variation | picograms per milliliter (pg/mL) | | Day 1 pre-dose and at multiple time points (up to 95 hours) post-dose in Treatment Period 1 | | | | ID | Title | Description |
|---|
| OG000 | [14C]TAK-831 50 μg | [14C]TAK-831 50 μg (approximately 1 μCi), infusion, 15-minute IV infusion, once on Day 1 of Treatment Period 1 after the TAK-831 oral dose, followed by a washout period of at least 7 days. |
| |
| Secondary | Period 1: Cmax: Maximum Observed Plasma Concentration for TAK-831 After Oral Administration | | PK-evaluable population included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile. Participants who received the oral dose of TAK-831 5 X 100 mg tablets in Treatment Period 1 were evaluated for this outcome measure. | Posted | | Geometric Mean | Geometric Coefficient of Variation | ng/mL | | Day 1 pre-dose and at multiple time points (up to 96.5 hours) post-dose in Treatment Period 1 | | | | ID | Title | Description |
|---|
| OG000 | TAK-831 500 mg | TAK-831 500 mg, tablet, orally, once on Day 1 of Treatment Period 1. |
| |
| Secondary | Period 1: Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-831 After Oral Administration | | PK-evaluable population included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile. Participants who received the oral dose of TAK-831 5 X 100 mg tablets in Treatment Period 1 were evaluated for this outcome measure. | Posted | | Median | Full Range | hr | | Day 1 pre-dose and at multiple time points (up to 96.5 hours) post-dose in Treatment Period 1 | | | | ID | Title | Description |
|---|
| OG000 | TAK-831 500 mg | TAK-831 500 mg, tablet, orally, once on Day 1 of Treatment Period 1. |
| |
| Secondary | Period 1: AUCinf: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-831 After Oral Administration | | PK-evaluable population included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile. Participants who received the oral dose of TAK-831 5 X 100 mg tablets in Treatment Period 1 were evaluated for this outcome measure. | Posted | | Geometric Mean | Geometric Coefficient of Variation | nanogram hour/milliliter (ng*hr/mL) | | Day 1 pre-dose and at multiple time points (up to 96.5 hours) post-dose in Treatment Period 1 | | | | ID | Title | Description |
|---|
| OG000 | TAK-831 500 mg | TAK-831 500 mg, tablet, orally, once on Day 1 of Treatment Period 1. |
| |
| Secondary | Period 1: AUCinf: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for [14C]TAK-831 After IV Administration | | PK-evaluable population included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile. Participants who received the [14C]TAK-831 50 ug IV dose in Treatment Period 1 were evaluated for this outcome measure. | Posted | | Geometric Mean | Geometric Coefficient of Variation | pg*hr/mL | | Day 1 pre-dose and at multiple time points (up to 95 hours) post-dose in Treatment Period 1 | | | | ID | Title | Description |
|---|
| OG000 | [14C]TAK-831 50 μg | [14C]TAK-831 50 μg (approximately 1 μCi), infusion, 15-minute IV infusion, once on Day 1 of Treatment Period 1 after the TAK-831 oral dose, followed by a washout period of at least 7 days. |
| |
| Secondary | Period 1: AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to Last Quantifiable Concentration for TAK-831 After Oral Administration | | PK-evaluable population included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile. Participants who received the oral dose of TAK-831 5 X 100 mg tablets in Treatment Period 1 were evaluated for this outcome measure. | Posted | | Geometric Mean | Geometric Coefficient of Variation | ng*hr/mL | | Day 1 pre-dose and at multiple time points (up to 96.5 hours) post-dose in Treatment Period 1 | | | | ID | Title | Description |
|---|
| OG000 | TAK-831 500 mg | TAK-831 500 mg, tablet, orally, once on Day 1 of Treatment Period 1. |
| |
| Secondary | Period 1: AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to Last Quantifiable Concentration for [14C]TAK-831 After IV Administration | | PK-evaluable population included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile. Participants who received the [14C]TAK-831 50 ug IV dose in Treatment Period 1 were evaluated for this outcome measure. | Posted | | Geometric Mean | Geometric Coefficient of Variation | pg*hr/mL | | Day 1 pre-dose and at multiple time points (up to 95 hours) post-dose in Treatment Period 1 | | | | ID | Title | Description |
|---|
| OG000 | [14C]TAK-831 50 μg | [14C]TAK-831 50 μg (approximately 1 μCi), infusion, 15-minute IV infusion, once on Day 1 of Treatment Period 1 after the TAK-831 oral dose, followed by a washout period of at least 7 days. |
| |
| Secondary | Period 1: t(1/2)z: Terminal Disposition Half-life for TAK-831 After Oral and [14C]TAK-831 After IV Administration in Plasma | | PK-evaluable population included all participants who complied sufficiently with the protocol and displayed an evaluable PK profile. Participants who received the oral dose of TAK-831 5 X 100 mg tablets and [14C]TAK-831 50 ug IV dose in Treatment Period 1 were evaluated for this outcome measure. | Posted | | Mean | Standard Deviation | hr | | Day 1 pre-dose and at multiple time points (up to 96.5 hours for TAK-831 and up to 95 hours for [14C]TAK-831) post-dose | | | | ID | Title | Description |
|---|
| OG000 | TAK-831 500 mg | TAK-831 500 mg, tablet, orally, once on Day 1 of Treatment Period 1. | | OG001 | [14C]TAK-831 50 μg | [14C]TAK-831 50 μg (approximately 1 μCi), infusion, 15-minute IV infusion, once on Day 1 of Treatment Period 1 after the TAK-831 oral dose, followed by a washout period of at least 7 days. |
| |
| Secondary | Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) | An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (example, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A TEAE is defined as an AE with an onset that occurs after receiving study drug. | Safety Population included all participants who received at least one dose of the study drug. Data is reported as per the treatment received in Treatment Periods 1 and 2. | Posted | | Count of Participants | | Participants | | From first dose of study drug up to 30 days after last dose of study drug (up to approximately 38 days) | | | | ID | Title | Description |
|---|
| OG000 | TAK-831 500 mg | TAK-831 500 mg, tablet, orally, once on Day 1 of Treatment Period 1. | | OG001 | [14C]TAK-831 50 μg | [14C]TAK-831 50 μg (approximately 1 μCi), infusion, 15-minute IV infusion, once on Day 1 of Treatment Period 1 after the TAK-831 oral dose, followed by a washout period of at least 7 days. | | OG002 | [14C]TAK-831 500 mg |
|
| Secondary | Number of Participants With TEAEs Related to Electrocardiogram (ECG) | The ECG parameters were considered TEAEs if they were judged to be clinically significant (i.e., if some action or intervention was required or if the Investigator judged the change to be beyond the range of normal physiologic fluctuation). | Safety Population included all participants who received at least one dose of the study drug and will be included in the safety evaluations. Data is reported as per the treatment received in Treatment Periods 1 and 2. | Posted | | Count of Participants | | Participants | | Up to Day 14 | | | | ID | Title | Description |
|---|
| OG000 | TAK-831 500 mg | TAK-831 500 mg, tablet, orally, once on Day 1 of Treatment Period 1. | | OG001 | [14C]TAK-831 50 μg | [14C]TAK-831 50 μg (approximately 1 μCi), infusion, 15-minute IV infusion, once on Day 1 of Treatment Period 1 after the TAK-831 oral dose, followed by a washout period of at least 7 days. | | OG002 | [14C]TAK-831 500 mg | [14C]TAK-831 500 mg (approximately 100 μCi), suspension, orally, under fasted state, once on Day 1 of Treatment Period 2. |
| |
| Secondary | Number of Participants With TEAEs Related to Vital Signs | Vital Signs included body temperature, respiratory rate, blood pressure, and heart rate. Any clinically significant changes from Baseline as assessed by the investigator were reported as TEAEs. | Safety Population included all participants who received at least one dose of the study drug and will be included in the safety evaluations. Data is reported as per the treatment received in Treatment Periods 1 and 2. | Posted | | Count of Participants | | Participants | | Up to Day 14 | | | | ID | Title | Description |
|---|
| OG000 | TAK-831 500 mg | TAK-831 500 mg, tablet, orally, once on Day 1 of Treatment Period 1. | | OG001 | [14C]TAK-831 50 μg | [14C]TAK-831 50 μg (approximately 1 μCi), infusion, 15-minute IV infusion, once on Day 1 of Treatment Period 1 after the TAK-831 oral dose, followed by a washout period of at least 7 days. | | OG002 | [14C]TAK-831 500 mg | [14C]TAK-831 500 mg (approximately 100 μCi), suspension, orally, under fasted state, once on Day 1 of Treatment Period 2. |
| |
| Secondary | Number of Participants With TEAEs Related to Laboratory Parameters | The laboratory parameters included parameters of hematology, serum checmistry and urinalysis. The laboratory parameters were considered TEAEs if their values were judged to be clinically significant (i.e., if some action or intervention was required or if the Investigator judged the change to be beyond the range of normal). | Safety Population included all participants who received at least one dose of the study drug and will be included in the safety evaluations. Data is reported as per the treatment received in Treatment Periods 1 and 2. | Posted | | Count of Participants | | Participants | | Up to Day 14 | | | | ID | Title | Description |
|---|
| OG000 | TAK-831 500 mg | TAK-831 500 mg, tablet, orally, once on Day 1 of Treatment Period 1. | | OG001 | [14C]TAK-831 50 μg | [14C]TAK-831 50 μg (approximately 1 μCi), infusion, 15-minute IV infusion, once on Day 1 of Treatment Period 1 after the TAK-831 oral dose, followed by a washout period of at least 7 days. | | OG002 | [14C]TAK-831 500 mg | [14C]TAK-831 500 mg (approximately 100 μCi), suspension, orally, under fasted state, once on Day 1 of Treatment Period 2. |
|